Chronic Obstructive Pulmonary Disease
📧 Sign up to get email alerts when something new happens for Chronic Obstructive Pulmonary Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-04-18FDA Approved: ROFLUMILAST — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approved the original ANDA for a generic roflumilast from Zydus Pharmaceuticals USA Inc., enabling a generic version of the COPD medicat…
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: Protein Biomarker Discovery and Validation in Chronic Obstructive Pulmonary Disease (COPD) And Asthma
A terminated clinical trial focusing on protein biomarker discovery and validation in asthma and COPD, with results posted in 2023.
-
FDA approval · 2023-04-17FDA Approved: ROFLUMILAST — Original Application (Aurobindo Pharma Limited)
FDA approved an original application for roflumilast from Aurobindo Pharma Limited, enabling a generic version of the COPD medication.
-
FDA approval · 2023-04-12FDA Approved: LEVALBUTEROL — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for levalbuterol by Mylan Pharmaceuticals, approving a change to the product under ANDA 078309.
-
CLINICAL_TRIALS trial_result · 2023-04-10Clinical Trial Update: Bioequivalence Study of Tiotropium Bromide Inhalation Powder [Phase 3]
Phase 3 bioequivalence study of tiotropium bromide inhalation powder has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-04-07Clinical Trial Update: Immunological Basis for Benralizumab Activity in Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]
Phase 2 trial investigating the immunological basis for benralizumab activity in chronic obstructive pulmonary disease (COPD).
-
CLINICAL_TRIALS trial_result · 2023-04-07Clinical Trial Update: Immunological Basis for Mepolizumab Activity in COPD [Phase 2]
Phase 2 clinical trial exploring the immunological basis for mepolizumab activity in chronic obstructive pulmonary disease.
-
CLINICAL_TRIALS trial_result · 2023-04-06Clinical Trial Update: Dexamethasone Versus Prednisone in Heart Failure Patients, Hospitalized With Exacerbation of Chronic Obstructive Pulmonary Disease. [Phase 4]
Phase 4 trial update comparing dexamethasone to prednisone in hospitalized chronic obstructive pulmonary disease patients with heart failure…
-
FDA approval · 2023-04-04FDA Approved: ROFLUMILAST — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' supplemental ANDA for roflumilast (generic roflumilast), expanding access to this COPD treatment as a g…
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD [Phase 4]
Phase 4 trial update evaluating CHF5993 and CHF1535 metered-dose inhalers on lung hyperinflation and exercise endurance in COPD patients.
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: Autologous Bronchial Basal Cell Transplantation for Treatment of COPD [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating autologous bronchial basal cell transplantation for chronic obstructive pulmonary disease has completed.
-
FDA approval · 2023-03-22FDA Approved: FORMOTEROL FUMARATE — Original Application (Lifestar Pharma LLC)
FDA approves the original application for Formoterol fumarate dihydrate supplied by Lifestar Pharma LLC. This generic product is approved fo…
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation [Phase 2]
Phase 2 trial update evaluating safety and efficacy of BCT197A2201 in COPD patients with exacerbation has been completed with results posted…
-
FDA approval · 2023-03-20FDA Approved: THEOPHYLLINE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved Amneal's Theophylline (generic) under an Original Application (ANDA 216276). Theophylline is indicated for relief of bronchospa…
-
CLINICAL_TRIALS trial_result · 2023-03-15Clinical Trial Update: The Addition of Inhaled Furosemide to Standard Treatment of COPD Exacerbation [Phase 3]
Phase 3 trial evaluating inhaled furosemide added to standard treatment for COPD exacerbation.
-
FDA approval · 2023-03-08FDA Approved: LEVALBUTEROL — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for levalbuterol products from Mylan Pharmaceuticals Inc. under the ANDA program. This action confir…
-
CLINICAL_TRIALS trial_result · 2023-03-06Clinical Trial Update: Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]
Phase 4 clinical trial update on inhaler lung deposition in COPD and asthma, with results posted after completion.
-
CLINICAL_TRIALS trial_result · 2023-03-06Clinical Trial Update: Effect of Noninvasive Ventilation on Physical Activity and Inflammation in COPD Patients [Phase 4]
Phase 4 trial exploring how noninvasive ventilation affects physical activity and inflammation in COPD patients with hypercapnia.
-
CLINICAL_TRIALS trial_result · 2023-03-03Clinical Trial Update: Acetazolamide to Prevent Impending Altitude-illness in Patients With COPD [Phase 3]
Phase 3 trial investigating acetazolamide to prevent impending altitude illness in patients with COPD.
-
CLINICAL_TRIALS trial_result · 2023-03-03Clinical Trial Update: Long-term Effect of an Health Education Program on Daily Physical Activity in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease [Phase 4]
A Phase 4 clinical trial update evaluating the long-term effect of a health education program on daily physical activity in patients with mo…
-
FDA approval · 2023-03-01FDA Approved: FLUTICASONE FUROATE ELLIPTA — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for Fluticasone Furoate Ellipta from Prasco Laboratories.
-
CLINICAL_TRIALS trial_result · 2023-02-28Clinical Trial Update: Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD [NA]
A terminated clinical trial evaluating bright light therapy for depressive symptoms in adults with cystic fibrosis and related conditions, w…
-
CLINICAL_TRIALS trial_result · 2023-02-27Clinical Trial Update: Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD [Phase 2]
Phase 2 trial update on pulsed inhaled nitric oxide for WHO Group 3 pulmonary hypertension associated with COPD has been completed.
-
CLINICAL_TRIALS withdrawal · 2023-02-23Clinical Trial Update: TOBacco STOP in Chronic Obstructive Pulmonary Disease-Trial - Study Protocol [Phase 4]
A Phase 4 clinical trial (TOBacco STOP in Chronic Obstructive Pulmonary Disease-Trial) has been withdrawn.
-
FDA approval · 2023-02-08FDA Approved: FLUTICASONE PROPIONATE AND SALMETEROL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for a generic inhaled fixed-dose combination of fluticasone propionate and salmeterol by Hikma P…